Skip to Content
Merck
CN
  • Disruption of microRNA-21 by TALEN leads to diminished cell transformation and increased expression of cell-environment interaction genes.

Disruption of microRNA-21 by TALEN leads to diminished cell transformation and increased expression of cell-environment interaction genes.

Cancer letters (2014-10-12)
Buyuan Chen, Xinji Chen, Xiwei Wu, Xiaoling Wang, Yingjia Wang, Ting-Yu Lin, Jessica Kurata, Jun Wu, Steven Vonderfecht, Guihua Sun, He Huang, Jiing-Kuan Yee, Jianda Hu, Ren-Jang Lin
ABSTRACT

MicroRNA-21 is dysregulated in many cancers and fibrotic diseases. Since miR-21 suppresses several tumor suppressor and anti-apoptotic genes, it is considered a cancer therapeutic target. Antisense oligonucleotides are commonly used to inhibit a miRNA; however, blocking miRNA function via an antagomir is temporary, often only achieves a partial knock-down, and may be complicated by off-target effects. Here, we used transcription activator-like effector nucleases (TALENs) to disrupt miR-21 in cancerous cells. Individual deletion clones were screened and isolated without drug selection. Sequencing and quantitative RT-PCR identified clones with no miR-21 expression. The loss of miR-21 led to subtle but global increases of mRNAs containing miR-21 target sequences. Cells without miR-21 became more sensitive to cisplatin and less transformed in culture and in mouse xenografts. In addition to the increase of PDCD4 and PTEN protein, mRNAs for COL4A1, JAG1, SERPINB5/Maspin, SMAD7, and TGFBI - all are miR-21 targets and involved in TGFβ and fibrosis regulation - were significantly upregulated in miR-21 knockout cells. Gene ontology and pathway analysis suggested that cell-environment interactions involving extracellular matrix can be an important miR-21 pathogenic mechanism. The study also demonstrates the value of using TALEN-mediated microRNA gene disruption in human pathobiological studies.

MATERIALS
Product Number
Brand
Product Description

USP
Transplatin, United States Pharmacopeia (USP) Reference Standard
Cisplatin impurity A, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
cis-Diamineplatinum(II) dichloride, ≥99.9% trace metals basis
Cisplatin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
Sigma-Aldrich
trans-Platinum(II)diammine dichloride
Sigma-Aldrich
cis-Diammineplatinum(II) dichloride, crystalline